Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00836706 · ClinicalTrials.gov registry record · Phase 1
Clarithromycin 500 mg Tablets Under Non-Fasting Conditions
A Phase 1 study, sponsored by Teva Pharmaceuticals USA.
- Completed
- Registry status
- Phase 1
- Development phase
- 24
- Enrollment target
NCT00836706: Completed Phase 1 study, sponsored by Teva Pharmaceuticals USA.
NCT00836706 is a Phase 1 study that has completed, run by Teva Pharmaceuticals USA. The registered enrollment target is 24 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00836706, a Phase 1 study, has completed, sponsored by Teva Pharmaceuticals USA.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 24 participants
- Enrollment target
Study Summary
This study will compare the relative bioavailability (rate and extent of absorption) of 500 mg Clarithromycin Tablets with that of 500 mg BIAXIN® Tablets following a single oral dose (1 x 500 mg tablet) in healthy adult subjects under non-fasting conditions.
Interventions
- DRUG clarithromycin
- DRUG BIAXIN®
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 24 participants |
| Start Date | 2002-07 |
| Est. Completion | 2002-07 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00836706
The ClinicalTrials.gov registry entry for NCT00836706 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 24 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Teva Pharmaceuticals USA, which has 83 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which clarithromycin is the first listed.
NCT00836706 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00836706 about?
NCT00836706 is a clinical study titled "Clarithromycin 500 mg Tablets Under Non-Fasting Conditions". This study will compare the relative bioavailability (rate and extent of absorption) of 500 mg Clarithromycin Tablets with that of 500 mg BIAXIN® Tablets following a single oral dose (1 x 500 mg tablet) in healthy adult subjects under non-fasting conditions.
What is the current status of trial NCT00836706?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 24 participants. The study started on 2002-07. Estimated completion is 2002-07.
What interventions are being tested in trial NCT00836706?
The interventions under investigation include: clarithromycin (DRUG), BIAXIN® (DRUG).
Who is sponsoring clinical trial NCT00836706?
This trial is sponsored by Teva Pharmaceuticals USA, which has 83 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.